Teratogenicity of Valproic Acid and Related Substances in the Mouse: Drug Accumulation and pHi in the Embryo During Organogenesis and Structure-Activity Considerations
The antiepileptic drug valproic acid is a putative human teratogen as suggested by retrospective studies (Robert and Rosa 1983; Lindhout and Meinardi 1984), a number of case reports (reviewed in Tein and McGregor 1985) and prospective investigations (Koch et al. 1983; Jäger-Roman et al. 1986; Nau et al. 1981a). The use of thus drug for seizure control during pregnancy was shown to result in an increased incidence of neural tube defects, in particular spina bifida aperta in addition to numerous other malformations, particularly of the face and the skeletal structures. Clinical doses range between 10–40 mg/kg/day administered as a single daily dose (Rowan et al. 1981) or in divided doses (Gjerloff et al. 1984). The therapeutic range is said to be between 50–100 µg/ml, although peak drug levels may be much higher: Rowan et al. (1981) reported peak levels of 180 µg/ml in a patient treated with a once-a-day dosing regimen. We have recently measured peak levels of 120 and 184µg/ml in two epileptic patients during the first trimester of pregnancy (Jäger-Roman et al. 1986).
KeywordsValproic Acid Neural Tube Defect Maternal Plasma Placental Transfer Acidic Drug
Unable to display preview. Download preview PDF.
- Brown NA (1987) Teratogenecity of carboxylic acids, distribution studies in whole embryo culture. In: Nau H, Scott WJ (eds) Pharmacokinetics in teratogenesis. CRC press, Boca Raton, Florida (in press)Google Scholar
- Collins MW, Scott W, Pitter E, Nau H, Wittfoht W (1986) Correlation of teratogenic potency with alteration of intracellular pH by C-8 carboxylic acids. Teratology 33:45CGoogle Scholar
- Mast TJ, Hendrickx AG, Nau H (1985) Teratology and pharmacokinetics of valproic acid in the rhesus monkey. Teratology 31:25AGoogle Scholar
- Moffa AM, White JA, Mackay EG, Frias JL (1984) Valproic acid, zinc and open neural tubes in 9 day-old hamster embryos. Teratology 29:47AGoogle Scholar
- Nau H (1986b) Species differences in pharmacokinetics and drug teratogenesis. Environ Health Persp in pressGoogle Scholar
- Nau H, Zierer R, Spielmann H, Neubert D, Gansau C (1981c) A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 29:2803–2814PubMedCrossRefGoogle Scholar
- Neubert D, Chahoud I (1985) Significance of species and strain differences in pre- and perinatal toxicology. Acta Histochem [Suppl] (Jena) 31:23–35Google Scholar
- Rowan AJ, Overweg J, Meijer JWA (1981) Monodose therapy with valproic acid: 24 h telemetric EEG and serum level studies. In: Dam M, Gram L, Penry JK (eds) Advances in epileptology. Raven, New York, pp 533–539Google Scholar
- Scott WJ, Nau H (1985) Weak acids as human teratogens: accumulation in the young mammalian embryo. Teratology 31:25AGoogle Scholar
- Scott WJ, Duggan CA, Schreiner CM, Collins MD, Nau H (1986) Intracellular pH of rodent embryos and its association with teratogenic response. In: Welsch F (ed) Approaches to evaluate mechanisms in teratogenesis. Hemisphere, WashingtonGoogle Scholar
- Wilson JG (1965) Embryological considerations in teratology. In: Wilson JG, Warkany J (eds) Teratology: principles and techniques. University of Chicago Press, ChicagoGoogle Scholar